증거 접근 및 네트워크 분야 인공지능(AI) : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the aI in evidence access and networks market size is projected to expand from USD 0.88 billion in 2025 to USD 1.00 billion in 2026 and is expected to reach USD 2.22 billion by 2031, with the CAGR over 2026-2031 projected to be 17.19%.

This report is Segmented by Component (Data Platforms and Networks, Analytics and Services), Data Source (Electronic Health Records, and Others), Technology (Natural Language Processing (NLP), and Others), End User (Pharmaceutical and Biotech Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Others). The Market Forecasts are Provided in Terms of Value (USD).

Global AI In Evidence Access And Networks Market Trends and Insights

Rising Regulatory Acceptance of RWE in Drug Approvals

The FDA already counted 23 approvals supported primarily by RWE through 2025, confirming that observational data can secure label expansions without fresh randomized trials. March 2026 saw the ICH M14 guideline define fit-for-purpose data and causal-inference design, placing stringent but clear rails around AI in evidence access and networks market submissions. In parallel, the EMA's DARWIN EU added 30 partners covering 180 million patients, turning federation into Europe's default architecture. Japan, China and Canada each published RWE playbooks, compressing global timelines for post-approval safety and effectiveness signals. Sponsors now view continuous evidence generation as a baseline obligation, driving sustained spend on harmonized data networks.

Exponential Growth of EHR and Claims Data Volumes

Healthcare created 175 exabytes of data in 2025, a sevenfold jump from 2018, with roughly 80% locked in unstructured notes and images. U.S. hospitals alone generate about 50 petabytes yearly, challenging legacy SQL warehouses. The HL7 FHIR-to-OMOP guide, published April 2026, finally standardizes mappings between clinical and observational models, allowing the AI in evidence access and networks market to query multi-site datasets without bespoke extract-transform-load (ETL) code. Simultaneously, AI adjudication engines trimmed claims-processing cycles, swelling structured billing records that fuel outcomes research. This data deluge compels vendors to scale tokenization, de-identification and NLP pipelines capable of onboarding petabytes while meeting privacy statutes.

Stringent Data-Privacy Regulations (HIPAA, GDPR, etc.)

A single healthcare breach averaged USD 9.3 million in 2023 and carried a 287-day discovery lag, amplifying compliance budgets across the AI in evidence access and networks market. GDPR fines cap at 4% of global revenue, pushing vendors to host duplicate European data lakes that inflate cost structures. China's Personal Information Protection Law and India's Digital Personal Data Protection Act require in-country processing, fracturing multiregional evidence loops. Tokenization tools mitigate risk yet add license fees many mid-tier CROs cannot shoulder, slowing platform migrations.

Other drivers and restraints analyzed in the detailed report include:

1. Pharma Demand for Accelerated Trial Design and Post-Marketing Studies
2. Integration of AI/ML for Rapid Insight Generation
3. Fragmented and Non-Interoperable Healthcare Data Sources

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Data platforms and networks generated USD 0.48 billion, equal to 54.57% of 2025 revenue in the AI in evidence access and networks market size, underscoring the up-front spend required for ingesting, tokenizing and federating petabyte-scale data. However, analytics and services are forecasted to post an 18.34% CAGR to 2031 as sponsors divert budgets from raw infrastructure to interpretable insights. Oracle's Life Sciences AI Data Platform blends 129 million de-identified records with agentic models, signaling the pivot toward decision support. Flatiron's Veeva EDC linkage cut form-completion time to 37 seconds, proving service layers can eliminate sponsor labor. Vendors that unite platform and consulting stacks-Datavant + Aetion, Tempus + Deep 6 AI-lock in multi-year deals that stabilize cash flows.

Competitive pressure mounts as storage costs fall and open-source federated learning frameworks spread. Service firms counter commoditization by embedding proprietary explainable-AI modules. FDA's documentation mandates magnify demand for regulatory consulting, and CROs increasingly white-label platform access, blurring value-chain borders. Consequently, services will account for a rising slice of AI in evidence access and networks market revenue even as platform fees recede.

Electronic health records contributed 60.25% of 2025 revenue, reflecting their clinical granularity, yet claims-based feeds are projected to outpace at 19.42% CAGR to 2031 and should capture a larger portion of AI in evidence access and networks market size for payer analytics. Komodo's CMS Innovator's License delivered de-identified claims for 130 million beneficiaries, a trove competitors cannot easily replicate. Symphony Health merges 68 billion annual transactions into longitudinal pathways, making claims indispensable for adherence and cost analyses.

Genomics and wearables remain nascent but fast growing. Tempus weaves molecular data from 6.5 million patients into real-world outcomes, and Apple's 419,297-participant Heart Study validated large-scale sensor endpoints. As precision-medicine pipelines multiply, omics feeds will expand their ownership of AI in evidence access and networks market share, albeit from a low base.

Geography Analysis

North America contributed 48.31% of 2025 AI in evidence access and networks market revenue, fueled by FDA RWE guidance, rich payer datasets and the CMS interoperability pledge requiring FHIR APIs by July 2026. Datavant's 300-partner ecosystem and Optum's comprehensive claims mart demonstrate regional infrastructure maturity. Canada's pan-Canadian Health Data Charter aims to harmonize provincial exchanges, while Mexico's social-security network covers 50 million beneficiaries but lacks tight EHR integration.

Europe benefits from DARWIN EU's 180 million-patient federation and national assets like the UK's OpenSAFELY and France's Health Data Hub. GDPR imposes costly localization, yet academic-industry coalitions compensate with public-sector scale. Germany's Medical Informatics Initiative connects university hospitals, although southern states move slower. Vendors willing to navigate multi-layered governance gain access to contiguous continental cohorts that rival U.S. volumes.

Asia-Pacific is expected to grow at a 20.12% CAGR through 2031, the fastest among regions, bolstered by China's 21-province RWE pilots and India's 580 million digital health accounts. Japan's PMDA guidance clarifies real-world data submissions and Singapore's 100% EHR adoption provides a high-fidelity sandbox. Localization laws in China and India force in-country processing, yet domestic cloud vendors and startup networks proliferate to fill the gap. Australia and South Korea approach near-universal digital records but grapple with regional governance, while GCC nations launch national EHR blueprints that will mature after 2028. Collectively, these moves embed structural tailwinds for AI in evidence access and networks market expansion across the hemisphere.

1. Aetion
2. Datavant
3. Elsevier
4. Evidation Health
5. Flatiron Health
6. HealthVerity
7. Inovalon
8. IQVIA
9. Komodo Health
10. Merative
11. Optum (UnitedHealth Group)
12. Oracle
13. SAS Institute
14. Symphony Health (ICON)
15. Syneos Health
16. Tempus Labs
17. TriNetX
18. Veradigm

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Regulatory Acceptance of RWE in Drug Approvals
  • 4.2.2 Exponential Growth of EHR and Claims Data Volumes
  • 4.2.3 Pharma Demand for Accelerated Trial Design and Post-Marketing Studies
  • 4.2.4 Integration of AI/ML for Rapid Insight Generation
  • 4.2.5 Decentralized Trials Boosting Federated Data-Network Adoption
  • 4.2.6 Outcomes-Based Payer Contracts Needing Robust Evidence Platforms
• 4.3 Market Restraints
  • 4.3.1 Stringent Data-Privacy Regulations (HIPAA, GDPR, Etc.)
  • 4.3.2 Fragmented and Non-Interoperable Healthcare Data Sources
  • 4.3.3 High Upfront Costs of Secure Evidence-Network Build-Outs
  • 4.3.4 Regulator Concerns on Data Provenance and Algorithm Transparency
• 4.4 Value-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Component
  • 5.1.1 Data Platforms and Networks
  • 5.1.2 Analytics and Services
• 5.2 By Data Source
  • 5.2.1 Electronic Health Records (EHR)
  • 5.2.2 Claims and Billing Data
  • 5.2.3 Genomic and Omics Data
  • 5.2.4 Patient Registries
  • 5.2.5 Others
• 5.3 By Technology
  • 5.3.1 Natural Language Processing (NLP)
  • 5.3.2 Machine Learning (ML) and Predictive Analytics
  • 5.3.3 Others
• 5.4 By End User
  • 5.4.1 Pharmaceutical and Biotech Companies
  • 5.4.2 Contract Research Organizations (CROs)
  • 5.4.3 Healthcare Providers and Payers
  • 5.4.4 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Aetion
  • 6.3.2 Datavant
  • 6.3.3 Elsevier
  • 6.3.4 Evidation Health
  • 6.3.5 Flatiron Health
  • 6.3.6 HealthVerity
  • 6.3.7 Inovalon
  • 6.3.8 IQVIA
  • 6.3.9 Komodo Health
  • 6.3.10 Merative
  • 6.3.11 Optum (UnitedHealth Group)
  • 6.3.12 Oracle
  • 6.3.13 SAS Institute
  • 6.3.14 Symphony Health (ICON)
  • 6.3.15 Syneos Health
  • 6.3.16 Tempus Labs
  • 6.3.17 TriNetX
  • 6.3.18 Veradigm

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment